November 2017 Vol 10, No 8

"Opioids Equal Heroin"

David B. Nash, MD, MBA

Clinical, Original Research

Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor

JoAnne Foody, MD; Robin S. Turpin, PhD; Beni A. Tidwell, BS; Debra Lawrence, PhD; Kathy L. Schulman, MS

Stakeholder Perspective

The Growing Role of Real-World Evidence in Clinical Decision-Making

Gary M. Owens, MD

Business, Original Research

Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors

Rajeev Ayyagari, PhD; Maureen Neary, PhD, MS; Shang Li, MS; Ariel Rokito, BS; Hongbo Yang, PhD; Jipan Xie, MD, PhD; Al B. Benson III, MD, FACP, FASCO

Industry Trends

The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers

Peter R. Fendt, PharmD, MBA; Brian Ung, PharmD, RPh; F. Randy Vogenberg, RPh, PhD

Results 1 - 4 of 4

Copyright © Engage Healthcare Communications, LLC. All rights reserved.